Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 June 2018

June 29, 2018 – The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended nine medicines for approval, including six orphan medicines1, at its June 2018 meeting. The CHMP recommended granting marketing authorisations for the first two chimeric antigen receptors (CAR) T-cell therapies in the European Union: Tisagenlecleucel and axicabtagene ciloleucel are both advanced therapy medicinal products … (leggi tutto)